A potential limitation of T-cell co-stimulation by current immune checkpoint inhibitors is a tumor milieu enriched with TGFβ, which strongly correlated with FOXP3 expression in our analysis of The Cancer Genome Atlas (TCGA) data set of diverse human cancers, including melanoma and breast cancer. Here, FOXP3 is linked to breast carcinoma.